Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study

Abstract

BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) varies widely. Although the GAP model is useful for predicting mortality, survivals have not yet been validated for each GAP score. We aimed to elucidate how prognosis is related to GAP score and GAP stage in IPF patients.

METHODS: The Korean Interstitial Lung Disease Study Group conducted a national survey to evaluate various characteristics in IPF patients from 2003 to 2007. Patients were diagnosed according to the 2002 criteria of the ATS/ERS. We enrolled 1,685 patients with IPF; 1,262 had undergone DLCO measurement. Patients were stratified based on GAP score (0-7): GAP score Group 0 (n?=?26), Group 1 (n?=?150), Group 2 (n?=?208), Group 3 (n?=?376), Group 4 (n?=?317), Group 5 (n?=?138), Group 6 (n?=?39), and Group 7 (n?=?8).

RESULTS: Higher GAP score and GAP stage were associated with a poorer prognosis (p?<?0.001, respectively). Survival time in Group 3 was lower than those in Groups 1 and 2 (p?=?0.043 and p?=?0.039, respectively), and higher than those in groups 4, 5, and 6 (p?=?0.043, p?=?0.032, and p?=?0.003, respectively). Gender, age, and DLCO (%) differed significantly between Groups 2 and 3. All four variables in the GAP model differed significantly between Groups 3 and 4.

CONCLUSION: The GAP system showed significant predictive ability for mortality in IPF patients. However, prognosis in IPF patients with a GAP score of 3 were significantly different from those in the other stage I groups and stage II groups of Asian patients.